Currently more than 70 biosimilar mAbs (monoclonal antibodies) are under development and multiple originator mAbs are going off-patent. Protein A resin remains the most important workhorse for the purification of monoclonal antibodies. Protein A resin has a high impact on both development and manufacturing cost, in particular during early stage clinical phases. This application note summarizes the key performance parameters for our high capacity protein A resin, Amsphere A3, for 6 biosimilar molecules of which five are mAbs and one is a Fc-fusion protein.
.png?width=300&height=71&name=JSR%20LS%20White%20Horizontal%20Logo%202019OCT62019%20(1).png)
.png?width=150&height=36&name=JSR%20LS%20White%20Horizontal%20Logo%202019OCT62019%20(1).png "JSR LS White Horizontal Logo 2019OCT62019 (1)"){kind=small}